Search

Your search keyword '"Townend, Jonathan"' showing total 609 results
Start Over Author "Townend, Jonathan"
609 results on '"Townend, Jonathan"'

1. Coronary Atherosclerotic Plaque Activity and Risk of Myocardial Infarction

Author

Wang, Kang-Ling, Balmforth, Craig, Meah, Mohammed N., Daghem, Marwa, Moss, Alastair J., Tzolos, Evangelos, Kwiecinski, Jacek, Molek-Dziadosz, Patrycja, Craig, Neil, Bularga, Anda, Adamson, Philip D., Dawson, Dana K., Arumugam, Parthiban, Sabharwal, Nikant K., Greenwood, John P., Townend, Jonathan N., Calvert, Patrick A., Rudd, James H.F., Verjans, Johan W., Berman, Daniel S., Slomka, Piotr J., Dey, Damini, Mills, Nicholas L., van Beek, Edwin J.R., Williams, Michelle C., Dweck, Marc R., and Newby, David E.

Published
2024
Full Text
View/download PDF

9. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial

Author

Ahmed, Husnat, Arthur, Peter, Aziz, Jane, Barnes, Lawrence, Boyle, Sarah, Brighton, Tom, Brown, Morris, Caulfield, Mark, Dawson, Jesse, Denvir, Martin, Doney, Alexander SF, Doshi, Sagar, Dryburgh, Moira, Eddleston, Michael, Finlayson, Jim, Fuat, Ahmet, Furnace, Jacqueline, Grieve, JW Kerr, Guthrie, Greg, Ham, Sharon, Isaard, Emma, Jennings, Claudine, Johnson, Richard, Kerr, Claire, Khan, Sohail, Krishnan, Kailash, Long, Susan, Mackintosh, Anne, Macleod, Mary Joan, McCormack, Terry, McEleny, Paul, Morar, Monique, Nadir, Adnan, Newby, David, Petrie, Colin, Preiss, David, Ralston, Stuart, Randall, Marc, Routledge, Helen, Shakir, Saad, Sharma, Raj, Shepherd, Bridget, Sims, Don, Snedden, Gordon, Trevelyan, Jasper, Weir, Christopher, Weir, Robin, Wetherall, Kirsty, Wilson, Robbie, Wilson, Adam, Zutis, Kris, Mackenzie, Isla S, Hawkey, Christopher J, Ford, Ian, Greenlaw, Nicola, Pigazzani, Filippo, Rogers, Amy, Struthers, Allan D, Begg, Alan G, Wei, Li, Avery, Anthony J, Taggar, Jaspal S, Walker, Andrew, Duce, Suzanne L, Barr, Rebecca J, Dumbleton, Jennifer S, Rooke, Evelien D, Townend, Jonathan N, Ritchie, Lewis D, and MacDonald, Thomas M

Published
2022
Full Text
View/download PDF

11. Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial

Author

Hill, Nathan R., Lasserson, Daniel, Thompson, Ben, Perera-Salazar, Rafael, Wolstenholme, Jane, Bower, Peter, Blakeman, Thomas, Fitzmaurice, David, Little, Paul, Feder, Gene, Qureshi, Nadeem, Taal, Maarten, Townend, Jonathan, Ferro, Charles, McManus, Richard, and Hobbs, F. D. Richard

Published
2022
Full Text
View/download PDF

14. Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation

Author

Mackenzie, Isla S, primary, Hawkey, Christopher J, additional, Ford, Ian, additional, Greenlaw, Nicola, additional, Pigazzani, Filippo, additional, Rogers, Amy, additional, Struthers, Allan D, additional, Begg, Alan G, additional, Wei, Li, additional, Avery, Anthony J, additional, Taggar, Jaspal S, additional, Walker, Andrew, additional, Duce, Suzanne L, additional, Barr, Rebecca J, additional, Dumbleton, Jennifer S, additional, Rooke, Evelien D, additional, Townend, Jonathan N, additional, Ritchie, Lewis D, additional, and MacDonald, Thomas M, additional

Published
2024
Full Text
View/download PDF

19. A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury

Author

James, Matthew T, Grams, Morgan E, Woodward, Mark, Elley, C Raina, Green, Jamie A, Wheeler, David C, de Jong, Paul, Gansevoort, Ron T, Levey, Andrew S, Warnock, David G, Sarnak, Mark J, Tonelli, Marcello, Hemmelgarn, Brenda R, Turin, Tanvir Chowdhury, Coresh, Josef, Matsushita, Kunihiro, Grams, Morgan, Sang, Yingying, Shlipak, Michael, Katz, Ronit, Emberson, Jonathan, Landray, Martin J, Townend, Jonathan N, Green, Jamie, Kirchner, H Les, Perkins, Robert, Chang, Alex R, Romundstad, Solfrid, Aasarød, Knut, Øien, Cecilia M, Hallan, Stein, Smith, David H, Thorp, Micah L, Johnson, Eric S, Chodick, Gabriel, Herzel, Esma, Katz, Rachel, Shalev, Varda, Bakker, Stephan JL, Heerspink, Hiddo J Lambers, van der Harst, Pim, Jee, Sun Ha, Kimm, Heejin, Mok, Yejin, Tangri, Navdeep, Naimark, David, Ärnlöv, Johan, Larsson, Anders, Lannfelt, Lars, Kovesdy, Csaba P, Kalantar-Zadeh, Kamyar, de Jong, Paul E, Iseki, Kunitoshi, Stengel, Benedicte, Warnock, David, and Ballew, Shoshana H

Subjects
Nutrition, Kidney Disease, Clinical Research, Diabetes, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Metabolic and endocrine, Renal and urogenital, Acute Kidney Injury, Adult, Aged, Comorbidity, Diabetes Mellitus, Disease Progression, Female, Glomerular Filtration Rate, Humans, Hypertension, Incidence, Kidney Failure, Chronic, Male, Middle Aged, Prognosis, Renal Insufficiency, Chronic, Estimated glomerular filtration rate, renal function, albuminuria, albumin-creatine ratio, diabetes, hypertension, acute kidney injury, acute renal failure, Chronic Kidney Disease Prognosis Consortium, meta-analysis, CKD Prognosis Consortium, Clinical Sciences, Public Health and Health Services, Urology & Nephrology
Abstract

BackgroundDiabetes mellitus and hypertension are risk factors for acute kidney injury (AKI). Whether estimated glomerular filtration rate (eGFR) and urine albumin-creatinine ratio (ACR) remain risk factors for AKI in the presence and absence of these conditions is uncertain.Study designMeta-analysis of cohort studies.Setting & population8 general-population (1,285,045 participants) and 5 chronic kidney disease (CKD; 79,519 participants) cohorts.Selection criteria for studiesCohorts participating in the CKD Prognosis Consortium.PredictorsDiabetes and hypertension status, eGFR by the 2009 CKD Epidemiology Collaboration creatinine equation, urine ACR, and interactions.OutcomeHospitalization with AKI, using Cox proportional hazards models to estimate HRs of AKI and random-effects meta-analysis to pool results.ResultsDuring a mean follow-up of 4 years, there were 16,480 episodes of AKI in the general-population and 2,087 episodes in the CKD cohorts. Low eGFRs and high ACRs were associated with higher risks of AKI in individuals with or without diabetes and with or without hypertension. When compared to a common reference of eGFR of 80mL/min/1.73m(2) in nondiabetic patients, HRs for AKI were generally higher in diabetic patients at any level of eGFR. The same was true for diabetic patients at all levels of ACR compared with nondiabetic patients. The risk gradient for AKI with lower eGFRs was greater in those without diabetes than with diabetes, but similar with higher ACRs in those without versus with diabetes. Those with hypertension had a higher risk of AKI at eGFRs>60mL/min/1.73m(2) than those without hypertension. However, risk gradients for AKI with both lower eGFRs and higher ACRs were greater for those without than with hypertension.LimitationsAKI identified by diagnostic code.ConclusionsLower eGFRs and higher ACRs are associated with higher risks of AKI among individuals with or without either diabetes or hypertension.

Published
2015

20. A Meta-analysis of the Association of Estimated GFR, Albuminuria, Age, Race, and Sex With Acute Kidney Injury

Author

Grams, Morgan E, Sang, Yingying, Ballew, Shoshana H, Gansevoort, Ron T, Kimm, Heejin, Kovesdy, Csaba P, Naimark, David, Oien, Cecilia, Smith, David H, Coresh, Josef, Sarnak, Mark J, Stengel, Benedicte, Tonelli, Marcello, Hemmelgarn, Brenda R, James, Matthew T, Turin, Tanvir Chowdhury, Matsushita, Kunihiro, Grams, Morgan, Shlipak, Michael, Katz, Ronit, Wheeler, David C, Emberson, Jonathan, Landray, Martin J, Townend, Jonathan N, Green, Jamie, Kirchner, H Les, Perkins, Robert, Chang, Alex R, Romundstad, Solfrid, Aasarød, Knut, Øien, Cecilia M, Hallan, Stein, Thorp, Micah L, Johnson, Eric S, Chodick, Gabriel, Herzel, Esma, Katz, Rachel, Shalev, Varda, Bakker, Stephan JL, Heerspink, Hiddo J Lambers, van der Harst, Pim, Jee, Sun Ha, Mok, Yejin, Tangri, Navdeep, Ärnlöv, Johan, Larsson, Anders, Lannfelt, Lars, Kalantar-Zadeh, Kamyar, de Jong, Paul E, Iseki, Kunitoshi, Levey, Andrew S, Warnock, David, and Woodward, Mark

Subjects
Clinical Research, Prevention, Kidney Disease, Renal and urogenital, Acute Kidney Injury, Adolescent, Adult, African Americans, Age Distribution, Aged, Albuminuria, Female, Glomerular Filtration Rate, Humans, Incidence, Male, Middle Aged, Predictive Value of Tests, Prognosis, Racial Groups, Severity of Illness Index, Sex Distribution, Whites, Young Adult, Estimated glomerular filtration rate, renal function, albuminuria, albumin-creatinine ratio, proteinuria, age, race/ethnicity, sex, acute kidney injury, acute renal failure, Chronic Kidney Disease Prognosis Consortium, meta-analysis, CKD Prognosis Consortium, White People, Black or African American, Clinical Sciences, Public Health and Health Services, Urology & Nephrology
Abstract

BackgroundAcute kidney injury (AKI) is a serious global public health problem. We aimed to quantify the risk of AKI associated with estimated glomerular filtration rate (eGFR), albuminuria (albumin-creatinine ratio [ACR]), age, sex, and race (African American and white).Study designCollaborative meta-analysis.Setting & population8 general-population cohorts (1,285,049 participants) and 5 chronic kidney disease (CKD) cohorts (79,519 participants).Selection criteria for studiesAvailable eGFR, ACR, and 50 or more AKI events.PredictorsAge, sex, race, eGFR, urine ACR, and interactions.OutcomeHospitalized with or for AKI, using Cox proportional hazards models to estimate HRs of AKI and random-effects meta-analysis to pool results.Results16,480 (1.3%) general-population cohort participants had AKI over a mean follow-up of 4 years; 2,087 (2.6%) CKD participants had AKI over a mean follow-up of 1 year. Lower eGFR and higher ACR were strongly associated with AKI. Compared with eGFR of 80mL/min/1.73m(2), the adjusted HR of AKI at eGFR of 45mL/min/1.73m(2) was 3.35 (95% CI, 2.75-4.07). Compared with ACR of 5mg/g, the risk of AKI at ACR of 300mg/g was 2.73 (95% CI, 2.18-3.43). Older age was associated with higher risk of AKI, but this effect was attenuated with lower eGFR or higher ACR. Male sex was associated with higher risk of AKI, with a slight attenuation in lower eGFR but not in higher ACR. African Americans had higher AKI risk at higher levels of eGFR and most levels of ACR.LimitationsOnly 2 general-population cohorts could contribute to analyses by race; AKI identified by diagnostic code.ConclusionsReduced eGFR and increased ACR are consistent strong risk factors for AKI, whereas associations of AKI with age, sex, and race may be weaker in more advanced stages of CKD.

Published
2015

22. Heart disease and stroke statistics 2023 update from the American Heart Association—implications for nephrology.

Author

Edwards, Nicola C, Ferro, Charles J, and Townend, Jonathan N

Subjects
HEART diseases, STROKE, DISEASE risk factors, CARDIOVASCULAR diseases risk factors, CHRONIC kidney failure, STATISTICS
Abstract

The annual American Heart Association (AHA) and National Institutes of Health statistical report details the most up to date statistics related to heart disease, stroke and cardiovascular risk factors, primarily within the USA. Although not a formal systematic review or meta-analysis, this 600 page report provides the most comprehensive and best summary of cardiovascular statistics for the year in question. Although data are collated from USA data registries, it serves as a critical resource for clinicians, policymakers, administrators and researchers in the northern and southern hemispheres. In this special report, we have chosen to highlight aspects of the document that are relevant to nephrologists, given the overlap of cardiovascular and renal disease. These include (i) key and emerging cardiovascular data signals in the general and chronic kidney disease (CKD) populations, (ii) ethnic and socio-economic disparity, (iii) environmental and behavioural factors that drive high levels of cardiovascular disease and which are key components of the AHA's eight components of the Life Essential cardiovascular health score, and (iv) the impact of COVID-19 both directly and indirectly on heart health. We provide some commentary and critical analysis of both the data and of the production of such data sets suggesting that similar data on CKD could also be published and linked to the AHA and other datasets. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Management of heart failure in patients with kidney disease—updates from the 2021 ESC guidelines.

Author

Edwards, Nicola C, Price, Anna M, Steeds, Richard P, Ferro, Charles J, and Townend, Jonathan N

Subjects
HEART failure, IMPLANTABLE cardioverter-defibrillators, ARTIFICIAL implants, KIDNEY diseases, HEART failure patients, KIDNEY failure, BUNDLE-branch block, CARDIAC pacing
Abstract

The wide overlap between the syndromes of chronic kidney disease (CKD) and chronic heart failure (HF) means that familiarity with the 2021 European Society of Cardiology guidelines is of importance to nephrologists. The common risk factors for the two syndromes together with the adverse cardiac structural remodelling associated with CKD means that many kidney disease patients experience breathlessness and fall within the HF phenotypes categorized in the guidelines. The management of HF is evolving rapidly leading to significant changes in the latest guideline iteration. The 2021 guidelines have changed from the 2016 version firstly by an increased focus on identifying the three phenotypes of HF to guide appropriate evidence-based management. Secondly, a new and simplified treatment algorithm for HF with reduced ejection fraction involving the rapid sequential initiation and up-titration of four 'pillars' of drug treatment—angiotensin-converting enzyme inhibitors or angiotensin-neprilysin inhibitors, beta blockers, mineralocorticoid receptor antagonists and now, thanks to convincing trial data, sodium-glucose co-transporter 2 inhibitors. Thirdly, guidelines for device therapy have been changed with down-graded advice on indications for primary prevention implantable cardioverter defibrillator therapy for patients with non-ischaemic HF and for cardiac resynchronization therapy with left bundle branch block (LBBB) and a QRS duration <150 ms. There are updated treatment plans for HF associated with non-cardiovascular comorbidities including CKD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury

Author

Tonelli, Marcello, Hemmelgarn, Brenda R., James, Matthew T., Turin, Tanvir Chowdhury, Coresh, Josef, Matsushita, Kunihiro, Grams, Morgan, Sang, Yingying, Shlipak, Michael, Sarnak, Mark J., Katz, Ronit, Wheeler, David C., Emberson, Jonathan, Landray, Martin J., Townend, Jonathan N., Green, Jamie, Kirchner, H. Les, Perkins, Robert, Chang, Alex R., Romundstad, Solfrid, Aasarød, Knut, Øien, Cecilia M., Hallan, Stein, Smith, David H., Thorp, Micah L., Johnson, Eric S., Chodick, Gabriel, Herzel, Esma, Katz, Rachel, Shalev, Varda, Gansevoort, Ron T., Bakker, Stephan J.L., Lambers Heerspink, Hiddo J., van der Harst, Pim, Jee, Sun Ha, Kimm, Heejin, Mok, Yejin, Tangri, Navdeep, Naimark, David, Ärnlöv, Johan, Larsson, Anders, Lannfelt, Lars, Kovesdy, Csaba P., Kalantar-Zadeh, Kamyar, de Jong, Paul E., Iseki, Kunitoshi, Levey, Andrew S., Stengel, Benedicte, Warnock, David, Woodward, Mark, Ballew, Shoshana H., Grams, Morgan E., Elley, C. Raina, Green, Jamie A., de Jong, Paul, and Warnock, David G.

Published
2015
Full Text
View/download PDF

34. A Meta-analysis of the Association of Estimated GFR, Albuminuria, Age, Race, and Sex With Acute Kidney Injury

Author

Tonelli, Marcello, Hemmelgarn, Brenda R., James, Matthew T., Turin, Tanvir Chowdhury, Coresh, Josef, Matsushita, Kunihiro, Grams, Morgan, Sang, Yingying, Shlipak, Michael, Sarnak, Mark J., Katz, Ronit, Wheeler, David C., Emberson, Jonathan, Landray, Martin J., Townend, Jonathan N., Green, Jamie, Kirchner, H. Les, Perkins, Robert, Chang, Alex R., Romundstad, Solfrid, Aasarød, Knut, Øien, Cecilia M., Hallan, Stein, Smith, David H., Thorp, Micah L., Johnson, Eric S., Chodick, Gabriel, Herzel, Esma, Katz, Rachel, Shalev, Varda, Gansevoort, Ron T., Bakker, Stephan J.L., Lambers Heerspink, Hiddo J., van der Harst, Pim, Jee, Sun Ha, Kimm, Heejin, Mok, Yejin, Tangri, Navdeep, Naimark, David, Ärnlöv, Johan, Larsson, Anders, Lannfelt, Lars, Kovesdy, Csaba P., Kalantar-Zadeh, Kamyar, de Jong, Paul E., Iseki, Kunitoshi, Levey, Andrew S., Stengel, Benedicte, Warnock, David, Woodward, Mark, Ballew, Shoshana H., Grams, Morgan E., and Oien, Cecilia

Published
2015
Full Text
View/download PDF

36. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data

Author

Matsushita, Kunihiro, Coresh, Josef, Sang, Yingying, Chalmers, John, Fox, Caroline, Guallar, Eliseo, Jafar, Tazeen, Jassal, Simerjot K, Landman, Gijs W D, Muntner, Paul, Roderick, Paul, Sairenchi, Toshimi, Schöttker, Ben, Shankar, Anoop, Shlipak, Michael, Tonelli, Marcello, Townend, Jonathan, van Zuilen, Arjan, Yamagishi, Kazumasa, Yamashita, Kentaro, Gansevoort, Ron, Sarnak, Mark, Warnock, David G, Woodward, Mark, and Ärnlöv, Johan

Published
2015
Full Text
View/download PDF

41. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial

Author

Mackenzie, Isla S, primary, Hawkey, Christopher J, additional, Ford, Ian, additional, Greenlaw, Nicola, additional, Pigazzani, Filippo, additional, Rogers, Amy, additional, Struthers, Allan D, additional, Begg, Alan G, additional, Wei, Li, additional, Avery, Anthony J, additional, Taggar, Jaspal S, additional, Walker, Andrew, additional, Duce, Suzanne L, additional, Barr, Rebecca J, additional, Dumbleton, Jennifer S, additional, Rooke, Evelien D, additional, Townend, Jonathan N, additional, Ritchie, Lewis D, additional, MacDonald, Thomas M, additional, Ahmed, Husnat, additional, Arthur, Peter, additional, Aziz, Jane, additional, Barnes, Lawrence, additional, Boyle, Sarah, additional, Brighton, Tom, additional, Brown, Morris, additional, Caulfield, Mark, additional, Dawson, Jesse, additional, Denvir, Martin, additional, Doney, Alexander SF, additional, Doshi, Sagar, additional, Dryburgh, Moira, additional, Eddleston, Michael, additional, Finlayson, Jim, additional, Fuat, Ahmet, additional, Furnace, Jacqueline, additional, Grieve, JW Kerr, additional, Guthrie, Greg, additional, Ham, Sharon, additional, Isaard, Emma, additional, Jennings, Claudine, additional, Johnson, Richard, additional, Kerr, Claire, additional, Khan, Sohail, additional, Krishnan, Kailash, additional, Long, Susan, additional, Mackintosh, Anne, additional, Macleod, Mary Joan, additional, McCormack, Terry, additional, McEleny, Paul, additional, Morar, Monique, additional, Nadir, Adnan, additional, Newby, David, additional, Petrie, Colin, additional, Preiss, David, additional, Ralston, Stuart, additional, Randall, Marc, additional, Routledge, Helen, additional, Shakir, Saad, additional, Sharma, Raj, additional, Shepherd, Bridget, additional, Sims, Don, additional, Snedden, Gordon, additional, Trevelyan, Jasper, additional, Weir, Christopher, additional, Weir, Robin, additional, Wetherall, Kirsty, additional, Wilson, Robbie, additional, Wilson, Adam, additional, and Zutis, Kris, additional

Published
2022
Full Text
View/download PDF

45. A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial

Author

Hayer, Manvir K., Edwards, Nicola C., Slinn, Gemma, Moody, William E., Steeds, Rick P., Ferro, Charles J., Price, Anna M., Andujar, Cecilio, Dutton, Mary, Webster, Rachel, Webb, David J., Semple, Scott, MacIntyre, Iain, Melville, Vanessa, Wilkinson, Ian B., Hiemstra, Thomas F., Wheeler, David C., Herrey, Anna, Grant, Margaret, Mehta, Samir, Ives, Natalie, and Townend, Jonathan N.

Published
2017
Full Text
View/download PDF

48. Changing trends in the incidence, management and outcomes of coronary artery perforation over an 11-year period: single-centre experience

Author

Umar, Hamza, primary, Sharma, Harish, additional, Osheiba, Mohammed, additional, Roy, Ashwin, additional, Ludman, Peter F, additional, Townend, Jonathan N, additional, Nadir, M Adnan, additional, Doshi, Sagar N, additional, George, Sudhakar, additional, Zaphiriou, Alex, additional, and Khan, Sohail Q, additional

Published
2022
Full Text
View/download PDF

49. A Longitudinal Study of Mitral Regurgitation Detected after Acute Myocardial Infarction

Author

Sharma, Harish, primary, Yuan, Mengshi, additional, Shakeel, Iqra, additional, Hodson, James, additional, Radhakrishnan, Ashwin, additional, Brown, Samuel, additional, May, John, additional, O’Connor, Kieran, additional, Zia, Nawal, additional, Doshi, Sagar N., additional, Hothi, Sandeep S., additional, Townend, Jonathan N., additional, Myerson, Saul G., additional, Ludman, Peter F., additional, Steeds, Richard P., additional, and Nadir, M. Adnan, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results